Protective effects of propofol against ischemia/reperfusion injury in rat kidneys.
OBJECTIVE
The purpose of this study was to investigate and compare the efficiency of propofol in the reduction of injury induced by free radicals in a rat model of renal ischemia/reperfusion (I/R).


METHODS
Twenty-four Wistar rats were divided into four groups in our study. Rats in the sham group underwent laparotomy and were made to wait for 120 min without ischemia. Rats in the control group were given nothing with ischemia-reperfusion. Rats in the I/R groups were given propofol (25 mg/kg) and 10% intralipid (250 mg/kg) ip, respectively, 15 min before the ischemia for 60 min followed by reperfusion for 60 min. The kidney tissues of the rats were taken under anesthesia at the end of the reperfusion period. Evaluation of biochemical malondialdehyde (MDA), superoxide dismutase, and catalase activities and histopathological analysis were performed with these samples.


RESULTS
I/R significantly increased MDA levels (p < 0.05). Histopathological findings of the control group confirmed that there was renal impairment by tubular cell swelling, interstitial edema, medullary congestion, and tubular dilatation. MDA levels were lower in the propofol group compared to control group (p < 0.05). In the propofol group, the level of histopathological scores is significantly decreased than control and intralipid groups in ischemia-reperfusion.


CONCLUSIONS
Our results demonstrate that I/R injury was significantly reduced in the presence of propofol. The protective effects of propofol may be due to their antioxidant properties. These results may indicate that propofol anesthesia protects against functional, biochemical, and morphological damage better than control in renal I/R injury.
Yuzbasioglu
Mehmet Fatih
MF
Department of General Surgery and Organ Transplantation, Faculty of Medicine, Kahramanmaras Sutcuimam University, Kahramanmaras 46050, Turkey. f_yuzbasioglu@hotmail.com
Aykas
Ahmet
A
Kurutas
Ergul Belge
EB
Sahinkanat
Tayfun
T
D018686:Anesthetics, Intravenous / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D002374:Catalase / Q000378:metabolism; D007668:Kidney / Q000098:blood supply* / Q000187:drug effects / Q000201:enzymology; D008315:Malondialdehyde / Q000378:metabolism; D015742:Propofol / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000517:prevention & control*; D013482:Superoxide Dismutase / Q000378:metabolism
D018686:Anesthetics, Intravenous; D008315:Malondialdehyde; D002374:Catalase; D013482:Superoxide Dismutase; D015742:Propofol